US regulators have accepted Bristol-Myers Squibb’s application to market its immunotherapy Opdivo plus Yervoy for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in certain patients.
News
Sanofi’s Dupixent approved for routine NHS use
Adults with moderate to severe atopic dermatitis are a step closer to being able to routinely access treatment with Sanofi’s Dupixent on the NHS, following a green light from cost regulators.
NICE u-turn backs Roche’s Ocrevus for multiple sclerosis
Roche’s Ocrevus has now won NICE backing as a treatment for relapsing–remitting multiple sclerosis in adults, having first been turned down by the cost watchdog.
‘Inappropriate’ painkiller prescribing shortened 456 lives at Gosport Hospital
More than 450 patients at Gosport War Memorial Hospital lost their lives early because they were inappropriately given powerful opioid analgesics, a public inquiry has concluded.
New PharmaTimes Sales Awards to deliver real world results
Designed to recognise the very best sales professionals in our industry today, the new PharmaTimes Sales Awards has piqued the industry’s interest, with a number of entries and nominations already received ahead of the 1 August closing date.
Anika hit by trial failure
US group Anika Therapeutics has been hit by the failure of its viscosupplement Cingal to hit targets in a Phase III trial comparing its effectiveness to a standard treatment in patients with osteoarthritis of the knee.
Shire bags paediatric label expansion for Cinryze in the US
US regulators have approved a label expansion for Shire’s Cinryze, allowing its use in children aged six and above with hereditary angioedema.
NHS ‘MOTs’ missing attendance, uptake and prescribing targets
Attendance, uptake and prescribing rates for NHS health checks are all lower than originally anticipated, according to a systematic review of data published in the British Journal of General Practice (BJGP).
AdoRx raises $10m for new cancer therapeutics
UK-based drug discovery AdoRx Therapeutics has raised $10 million to fund its work on identifying new cancer therapeutics, in an investment round financed by Epidarex Capital and CRT Pioneer Fund.
UK announces review of medicinal cannabis
Home secretary Sajid Javid has announced a review of medicinal cannabis in the UK, in response to growing pressure to allow use of cannabis oil to help control seizures in children with severe forms of epilepsy.
Pancreatic cancer survival much lower than thought, research finds
Pancreatic Cancer UK is calling for greater investment in research funding for pancreatic cancer as new data reveals that just three percent of patients with the most common form will survive beyond five years.
Novo, Kallyope link to develop obesity, diabetes therapies
Novo Nordisk and Kallyope are joining forces to discover novel peptide therapeutics for obesity and diabetes.
Amgen’s Blincyto gets full EU approval for rare leukaemia
European regulators have awarded Amgen’s Blincyto full approval for Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow thought to affect around 900 patients a year in the region.
US approves joint damage data for Cosentyx
US regulators have approved new evidence showing that Novartis’ Cosentyx significantly slows progression of joint structural damage in patients with active psoriatic arthritis (PsA).
Phase III success for Janssen’s esketamine in treatment-resistant depression
Janssen has presented data from pivotal Phase III clinical studies backing use of esketamine spray in treatment-resistant depression.
